Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Lipoprotein lipase (LPL) is a key regulator of triglyceride clearance. Its coordinated regulation during feeding and fasting is critical for maintaining lipid homeostasis and energy supply. Angiopoietin-like (Angptl)3 and Angptl4 are secreted proteins that have been demonstrated to regulate triglyceride metabolism by inhibiting LPL. We have taken a targeted genetic approach to generate Angptl4- and Angptl3-deficient mice as well as transgenic mice overexpressing human Angptl4 in the liver. The Angptl4 transgenic mice displayed elevated plasma triglycerides and reduced postheparin plasma (PHP) LPL activity. A purified recombinant Angptl4 protein inhibited mouse LPL and recombinant human LPL activity in vitro. In contrast to the transgenic mice, Angptl4-deficient mice displayed hypotriglyceridemia and increased PHP LPL activity, with greater effects in the fasted compared with the fed state. Angptl3-deficient mice also displayed hypotriglyceridemia with elevated PHP LPL activity, but these mice showed a greater effect in the fed state. Mice deficient in both Angptl proteins showed an additive effect on plasma triglycerides and did not survive past 2 months of age. Our results show that Angptl3 and Angptl4 function to regulate circulating triglyceride levels during different nutritional states and therefore play a role in lipid metabolism during feeding/fasting through differential inhibition of LPL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ANGPTL3 inhibits the lipoprotein lipase, which results in increased blood lipid levels [143–145].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“Evinacumab is a monoclonal antibody inhibiting angiopoietin-like 3 (ANGPTL3).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“In contrast to other pharmacological treatments, evinacumab’s MoA is therefore independent of the LDL-C receptor [143, 148], providing new options for more synergistic combination treatments.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“Thus, Angptl4 knockout mice have reduced plasma triglycerides, whereas Angptl4 overexpressing mice have increased triglyceride levels [9,10].”
From Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity (2015) · cites this paper as [9]
In the citing paper
“Conversely, ANGPTL4-deficient mice had lower than normal plasma triglycerides and higher postheparin-plasma LPL activity (16).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [16]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J., Irvine, S., & Ramji, D. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 927
Merkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 522
Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 489
Angptl3 regulates lipid metabolism in mice
Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H., & Furukawa, H. (2002) · Nature Genetics · doi:10.1038/ng814 · Cited by 379
Yoon, J. C., Chickering, T. W., Rosen, E. D., Dussault, B., Qin, Y., Soukas, A., Friedman, J. M., Holmes, W. E., & Spiegelman, B. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5343-5349.2000 · Cited by 356
Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 339
Yoshida, K., Shimizugawa, T., Ono, M., & Furukawa, H. (2002) · Journal of Lipid Research · doi:10.1194/jlr.c200010-jlr200 · Cited by 317
Kim, I., Kim, H.-G., Kim, H. W., Kim, H.-H., Park, S. K., Uhm, C.-S., Lee, Z. H., & Koh, G. Y. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460603 · Cited by 284
Weinstock, P. H., Bisgaier, C. L., Aalto-Setälä, K., Radner, H., Ramakrishnan, R., Levak-Frank, S., Essenburg, A. D., Zechner, R., & Breslow, J. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118319 · Cited by 254
Köster, A., Montkowski, A., Schulz, S., Stübe, E.-M., Knaudt, K., Jenck, F., Moreau, J.-L., Nothacker, H.-P., Civelli, O., & Reinscheid, R. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10444 · Cited by 247
Self-citationFan, J., Wang, J., Bensadoun, A., Lauer, S. J., Dang, Q., Mahley, R. W., & Taylor, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8724 · Cited by 240
Mandard, S., Zandbergen, F., Tan, N. S., Escher, P., Patsouris, D., Koenig, W., Kleemann, R., Bakker, A., Veenman, F., Wahli, W., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403058200 · Cited by 231
Estrogen suppresses transcription of lipoprotein lipase gene
Homma, H., Kurachi, H., Nishio, Y., Takeda, T., Yamamoto, T., Adachi, K., Morishige, K.-I., Ohmichi, M., Matsuzawa, Y., & Murata, Y. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.11404 · Cited by 209
Weinstock, P. H., Levak-Frank, S., Hudgins, L. C., Radner, H., Friedman, J. M., Zechner, R., & Breslow, J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10261 · Cited by 208
Protein Region Important for Regulation of Lipid Metabolism in Angiopoietin-like 3 (ANGPTL3)
Ono, M., Shimizugawa, T., Shimamura, M., Yoshida, K., Noji-Sakikawa, C., Ando, Y., Koishi, R., & Furukawa, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302861200 · Cited by 195
Asnicar, M. A. (2001) · Endocrinology · doi:10.1210/en.142.10.4394 · Cited by 177
Self-citationIdentification of a mammalian angiopoietin-related protein expressed specifically in liver
Conklin, D., Gilbertson, D., Taft, D. W., Maurer, M. F., Whitmore, T. E., Smith, D. L., Walker, K. M., Chen, L. H., Wattler, S., Nehls, M., et al. (1999) · Genomics · doi:10.1006/geno.1999.6041 · Cited by 169 · cited 4×
“NGIOPOIETIN-LIKE (ANGPTL) 3 and Angptl4 are secreted proteins with structural similarity to angiopoietins (1, 2) that have been shown to be potent inhibitors of lipoprotein lipase (LPL) (3, 4). Both proteins contain an Nterminal coiled-coil region and a C-terminal fibrinogen-like domain and are found in plasma both as…”
BackgroundInfluentialOligomerization and Regulated Proteolytic Processing of Angiopoietin-like Protein 4
Ge, H., Yang, G., Huang, L., Motola, D. L., Pourbahrami, T., & Li, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307583200 · Cited by 130
Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes
Shimamura, M., Matsuda, M., Kobayashi, S., Ando, Y., Ono, M., Koishi, R., Furukawa, H., Makishima, M., & Shimomura, I. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03058-9 · Cited by 117
The pivotal role of lipoprotein lipase in atherosclerosis
Mead, J. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00405-4 · Cited by 106
Regulation of the angiopoietin-like protein 3 gene by LXR
Kaplan, R., Zhang, T., Hernandez, M., Gan, F. X., Wright, S. D., Waters, M. G., & Cai, T.-Q. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200367-jlr200 · Cited by 106
Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4
Ge, H., Yang, G., Yu, X., Pourbahrami, T., & Li, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400138-jlr200 · Cited by 104
Asnicar, M. A., Köster, A., Heiman, M. L., Tinsley, F., Smith, D. P., Galbreath, E., Fox, N., Ma, Y. L., Blum, W. F., & Hsiung, H. M. (2002) · Endocrinology · doi:10.1210/en.2002-220354 · Cited by 103
Self-citationInhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart
Yu, X., Burgess, S. C., Ge, H., Wong, K. K., Nassem, R. H., Garry, D. J., Sherry, A. D., Malloy, C. R., Berger, J. P., & Li, C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409564102 · Cited by 94
Enhanced CD4+ T Cell Proliferation and Th2 Cytokine Production in DR6-Deficient Mice
Liu, J., Na, S., Glasebrook, A. L., Fox, N. W., Solenberg, P. J., Zhang, Q., Song, H. Y., & Yang, D. D. (2001) · Immunity · doi:10.1016/s1074-7613(01)00162-5 · Cited by 88
Self-citationANGPTL3 is increased in both insulin-deficient and -resistant diabetic states
Inukai, K., Nakashima, Y., Watanabe, M., Kurihara, S., Awata, T., Katagiri, H., Oka, Y., & Katayama, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.151 · Cited by 82
Bergö, M., Wu, G., Ruge, T., & Olivecrona, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200325200 · Cited by 69
Kratky, D., Zimmermann, R., Wagner, E. M., Strauss, J. G., Jin, W., Kostner, G. M., Haemmerle, G., Rader, D. J., & Zechner, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci15972 · Cited by 53
Regulation of lipoprotein lipase in different rat tissues
Kuwajima, M., Foster, D. W., & McGarry, J. (1988) · Metabolism · doi:10.1016/0026-0495(88)90178-3 · Cited by 49
Kratky, D., Zimmermann, R., Wagner, E. M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200515972 · Cited by 40
Nutritional regulation of lipoprotein lipase in mice
Ruge, T., Wu, G., Olivecrona, T., & Olivecrona, G. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00256-5 · Cited by 31
Hepatic and lipoprotein lipases selectively assayed in postheparin plasma
Henderson, A. D., Richmond, W., & Elkeles, R. S. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.2.218 · Cited by 30
Wagner, E. M., Kratky, D., Haemmerle, G., Hrzenjak, A., Kostner, G. M., Steyrer, E., & Zechner, R. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300293-jlr200 · Cited by 25
Shimada, M., Ishibashi, S., Yamamoto, K., Kawamura, M., Watanabe, Y., Gotoda, T., Harada, K., Inaba, T., Ohsuga, J.-I., Yazaki, Y., et al. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1878 · Cited by 23
A simple method for the separation of triacylglycerols from fatty acids released in lipase assays
Borensztajn, J., Reddy, M. N., & Gladstone, A. R. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38432-7 · Cited by 10
Seidman, J. G. (2012) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb2300s97 · Cited by 5
Cited by
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Lipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741
“Specifically, Angptl-3 and Angptl-4 inhibit LPL activity and are associated with hypertriglyceridemia (127; 136; 250).”
BackgroundEvinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Metadata
- Authors
- Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., Heuer, J. G., Jaskunas, S. R., & Eacho, P.
- Affiliations
- Eli Lilly (United States) (US)
- Takeda Oncology (United States) (US)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-11-01
- Volume
- 146
- Issue
- 11
- Pages
- 4943-4950
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2117617326
- Semantic Scholar
- 6382419c744ba19464b065395484df9cb3cf3eaf
- Cited by
- 427
- References
- 36
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 15 · 2022: 11 · 2021: 41 · 2020: 26 · 2019: 20 · 2018: 33 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 27 · 2013: 29 · 2012: 22
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- ANGPTL4, ANGPTL3, lipoprotein lipase, triglyceride metabolism, hypotriglyceridemia, plasma triglycerides, lipoprotein lipase inhibition, fasting and feeding, lipid homeostasis, knockout mice, transgenic mice
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 4, Angiopoietin-Like Protein 3, Animals, Fasting, Heparin, Humans, Hyperlipidemias, Lipoprotein Lipase, Mice, Transgenic, Recombinant Proteins, Triglycerides, Survival Analysis, Mice, Knockout, Postprandial Period, Intercellular Signaling Peptides and Proteins, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.